Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
GEHC · Nasdaq · X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Fundamental quality
53
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its profitability weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $17,585M | $2,247M | — | — |
| 2022 | $18,341M | $1,916M | — | $6,801M |
| 2023 | $19,552M | $1,568M | — | $6,944M |
| 2024 | $19,672M | $1,993M | — | $6,075M |
| 2025 | $20,625M | $2,084M | — | $5,505M |
Between 2021 and 2025, revenue went from $17,585M to $20,625M (+17%) and net income went from $2,247M to $2,084M (-7%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Ge Healthcare Technologies Inc. a profitable company?
Ge Healthcare Technologies Inc. is profitable, with a net margin of 9.1%, though a thin one.
Does Ge Healthcare Technologies Inc. have a lot of debt?
A moderate level: its net debt is 2.67 times its EBITDA.
Is Ge Healthcare Technologies Inc. growing?
Its revenue has grown 4.2% annualized in recent years.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Ge Healthcare Technologies Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →